ArticleCurrent microbiology2025
High-Level Scale Bioproduction of Prodigiosin Using a Novel Designed Culture Medium Completely Based on Organic By-Products and its Potential Anti-Alzheimer Effect: An Experimental and Virtual Study.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimization of Solid-State Fermentation Process for Prodigiosin Production from Soybean Residue UsingMicroorganisms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The red microbial pigment - prodigiosin has attracted much attention in research due to its multiple bioactivities, which can be applied in various fields. Production prodigiosin with an eco-friendly strategy is currently an interesting and prioritized research topic. This study introduces an innovative production approach utilizing a novel, eco-friendly culture medium system that completely replaces expensive commercial nutrients with a combination of low-cost organic byproducts (shrimp shell powder and groundnut oil cake). This new approach yielded a remarkably high prodigiosin concentration (7520 mg/L) in an exceptionally short cultivation time (8 h) during large-scale fermentation. Beyond sustainable production, this research identified a novel therapeutic potential for prodigiosin in managing Alzheimer's disease via its ability to block cholinesterase enzymes, which are key targets in Alzheimer's therapy. Besides the experimental approach, computational simulations were used to predict the drug-likeness, pharmacokinetics, and safety profiles of prodigiosin in two forms (neutral and cationic). Notably, molecular docking and DFT analysis revealed effective interactions of prodigiosin with cholinesterase enzymes, with the cationic form showing a more promising capacity for protein target interaction. This study provided scientific insights into the eco-friendly cultural medium for prodigiosin production, its anti-cholinesterase activity, and potential properties through virtual simulations.
Indexed as
Identifiers
41379242What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.